Black Diamond Therapeutics Granted Fast Track Designation By FDA For BDTX-189 For Treatment Of Adult Patients With A Solid Tumor Harboring An Allosteric HER2 Mutation Or An EGFR Or HER2 Exon 20 Insertion Mutation